Conflicting interactions of apolipoprotein A and high density lipoprotein cholesterol with microvascular complications of type 2 diabetes

Aryan, Zahra; Afarideh, Mohsen; Ghajar, Alireza; Esteghamati, Sadaf; Esteghamati, Alireza; Nakhjavani, Manouchehr

doi:10.1016/j.diabres.2017.07.037

Cited by 10 publications

(18 citation statements)

References 27 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…Of these, 16 were further excluded for the reasons listed in Figure 1 . Finally, eleven observational studies, including six prospective cohort studies ( 12 , 15 , 17 , 19 , 21 , 22 ), three cross-sectional studies ( 13 , 14 , 18 ), and two nested case-control studies ( 16 , 20 ), were included into the meta-analysis.…”

Section: Resultsmentioning

confidence: 99%

“…Overall, eleven studies with 9304 T2DM patients were included. The studies were performed in Korea ( 12 , 15 ), China ( 17 , 18 ), Japan ( 14 ), Iran ( 16 , 20 ), the United States ( 13 , 19 ), Denmark ( 21 ), and the Netherlands ( 22 ). The mean ages of the patients varied from 53 to 69 years.…”

Section: Resultsmentioning

confidence: 99%

“…Although early study has proposed that higher serum Lp (a) may also be associated with renal dysfunction in diabetic patients, subsequent studies evaluating the association between Lp (a) and diabetic nephropathy showed inconsistent results (10,11). Some studies suggested that serum Lp (a) is related to higher odds of diabetic nephropathy in T2DM patients (12)(13)(14)(15)(16)(17), while others did not (18)(19)(20)(21)(22). Therefore, relationship between Lp (a) level and diabetic nephropathy remains undetermined.…”

Section: Introductionmentioning

confidence: 99%

See 2 more Smart Citations

Association Between Lipoprotein (A) and Diabetic Nephropathy in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis

2021

View full text Add to dashboard Cite

BackgroundLipoprotein (a) [Lp (a)] has been well recognized as a risk factor of cardiovascular disease. However, the association between serum Lp (a) and diabetic nephropathy in patients with type 2 diabetes mellitus (T2DM) remains unknown. We performed a meta-analysis to comprehensively evaluate the above association.MethodsObservational studies aiming to evaluate the independent association between serum Lp (a) and diabetic nephropathy in T2DM patients were identified by systematic search of PubMed and Embase databases. A random-effect model which incorporated the potential intra-study heterogeneity was used for the meta-analysis.ResultsEleven observational studies with 9304 T2DM patients were included. Results showed that compared to those with the lowest Lp (a), patients with the highest Lp (a) level had higher odds of diabetic nephropathy (adjusted odds ratio [OR]: 1.63, 95% confidence interval [CI]: 1.25–2.14, I2 = 54%, P < 0.001). Meta-analysis of studies in which Lp (a) was presented as continuous variables showed consistent result (adjusted OR: 1.13 for 1 mg/dl increment of Lp (a), 95% CI: 1.03–1.24, I2 = 36%, P = 0.008). Subgroup analyses showed that study characteristics such as definitions of diabetic nephropathy and study design did not significantly affect the association (P for subgroup difference all > 0.05).ConclusionsHigher serum Lp (a) in patients with T2DM is independently associated with higher odds of diabetic nephropathy. Large scale prospective cohort studies are needed to validate this finding. Moreover, the potential influence of Lp (a) lowering on renal function in T2DM patients may be further investigated.

show abstract

Section: Resultsmentioning

confidence: 99%

Section: Resultsmentioning

confidence: 99%

Section: Introductionmentioning

confidence: 99%

See 1 more Smart Citation

Association Between Lipoprotein (A) and Diabetic Nephropathy in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis

2021

View full text Add to dashboard Cite

show abstract

“…The Copenhagen City Heart Study showed a 1.6-fold increased risk for incident myocardial infarction for Lp(a) levels between 30 and 76 mg/dl, corresponding to the 67th to 90th percentile, this further risk increased with higher Lp(a) levels [15]. Findings on the relationship of Lp(a) levels and microvascular complications in type 2 diabetes have been conflicting [16][17][18][19][20][21][22][23][24][25][26][27]. Most of these studies were of Asian populations and the generalisability of the findings to other ethnicities remains uncertain.…”

Section: Introductionmentioning

confidence: 99%

“…In diabetic nephropathy, two small prospective studies found Lp(a) to be positively associated with nephropathy [19,24], whereas another prospective study by Lin et al [25] did not find any association. Similarly, the few reports for diabetic neuropathy are also conflicting [26,27]. The association of known LPA SNPs and ApoA isoforms with microvascular complications in type 2 diabetes has never been investigated.…”

Section: Introductionmentioning

confidence: 99%

Lipoprotein(a) plasma levels are not associated with incident microvascular complications in type 2 diabetes mellitus

et al. 2020

View full text Add to dashboard Cite

Aims/hypothesis Microvascular disease in type 2 diabetes is a significant cause of end-stage renal disease, blindness and peripheral neuropathy. The strict control of known risk factors, e.g. lifestyle, hyperglycaemia, hypertension and dyslipidaemia, reduces the incidence of microvascular complications, but a residual risk remains. Lipoprotein (a) [Lp(a)] is a strong risk factor for macrovascular disease in the general population. We hypothesised that plasma Lp(a) levels and the LPA gene SNPs rs10455872 and rs3798220 are associated with the incident development of microvascular complications in type 2 diabetes. Methods Analyses were performed of data from the DiaGene study, a prospective study for complications of type 2 diabetes, collected in the city of Eindhoven, the Netherlands (n = 1886 individuals with type 2 diabetes, mean follow-up time = 6.97 years). To assess the relationship between plasma Lp(a) levels and the LPA SNPs with each newly developed microvascular complication (retinopathy n = 223, nephropathy n = 246, neuropathy n = 236), Cox proportional hazards models were applied and adjusted for risk factors for microvascular complications (age, sex, mean arterial pressure, non-HDL-cholesterol, HDL-cholesterol, BMI, duration of type 2 diabetes, HbA 1c and smoking). Results No significant associations of Lp(a) plasma levels and the LPA SNPs rs10455872 and rs3798220 with prevalent or incident microvascular complications in type 2 diabetes were found. In line with previous observations the LPA SNPs rs10455872 and rs3798220 did influence the plasma Lp(a) levels. Conclusions/interpretation Our data show no association between Lp(a) plasma levels and the LPA SNPs with known effect on Lp(a) plasma levels with the development of microvascular complications in type 2 diabetes. This indicates that Lp(a) does not play a major role in the development of microvascular complications. However, larger studies are needed to exclude minimal effects of Lp(a) on the development of microvascular complications.

show abstract

Lp(a) and Apo-lipoproteins as predictors for micro- and macrovascular complications of diabetes: A case-cohort study

Moosaie

Firouzabadi

Abouhamzeh

et al. 2020

Nutrition, Metabolism and Cardiovascular Diseases

View full text Add to dashboard Cite

Conflicting interactions of apolipoprotein A and high density lipoprotein cholesterol with microvascular complications of type 2 diabetes

Cited by 10 publications

References 27 publications

Association Between Lipoprotein (A) and Diabetic Nephropathy in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis

Association Between Lipoprotein (A) and Diabetic Nephropathy in Patients With Type 2 Diabetes Mellitus: A Meta-Analysis

Lipoprotein(a) plasma levels are not associated with incident microvascular complications in type 2 diabetes mellitus

Lp(a) and Apo-lipoproteins as predictors for micro- and macrovascular complications of diabetes: A case-cohort study

Contact Info

Product

Resources

About